| Literature DB >> 34141083 |
Enrico Speri1, Yuanyuan Qian1, Jeshina Janardhanan1, Cesar Masitas1, Elena Lastochkin1, Stefania De Benedetti1, Man Wang1, Valerie A Schroeder1, William R Wolter2, Allen G Oliver1, Jed F Fisher1, Shahriar Mobashery1, Mayland Chang1.
Abstract
Clostridioides difficile is a leading health threat. This pathogen initiates intestinal infections during gut microbiota dysbiosis caused by oral administration of antibiotics. C. difficile is difficult to eradicate due to its ability to form spores, which are not susceptible to antibiotics. To address the urgent need for treating recurrent C. difficile infection, antibiotics that selectively target C. difficile over common gut microbiota are needed. We herein describe the class of picolinamide antibacterials which show potent and selective activity against C. difficile. The structure-activity relationship of 108 analogues of isonicotinamide 4, a compound that is equally active against methicillin-resistant Staphylococcus aureus and C. difficile, was investigated. Introduction of the picolinamide core as exemplified by analogue 87 resulted in exquisite potency and selectivity against C. difficile. The ability of the picolinamide class to selectively target C. difficile and to prevent gut dysbiosis holds promise for the treatment of recurrent C. difficile infection.Entities:
Year: 2021 PMID: 34141083 PMCID: PMC8201750 DOI: 10.1021/acsmedchemlett.1c00135
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.632